FAIR VALUE MEASUREMENTS (Details 3) (Developed Markets, USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended	3 Months Ended
	Mar. 31, 2013 Amortization and Impairments of Finite-lived Intangible Assets Cortaid	Sep. 30, 2013 Corporate brands Amortization and Impairments of Finite-lived Intangible Assets	Sep. 30, 2013 Corporate brands Amortization and Impairments of Finite-lived Intangible Assets	Sep. 30, 2013 Non-recurring basis Amortization and Impairments of Finite-lived Intangible Assets Ezogabine Retigabine	Sep. 30, 2013 Non-recurring basis In-process Research and Development Impairments and Other Charges Ezogabine Retigabine	Sep. 30, 2013 Non-recurring basis Significant Unobservable Inputs (Level 3) Ezogabine Retigabine	Sep. 30, 2013 Non-recurring basis Significant Unobservable Inputs (Level 3) Suncare and skincare brands	Mar. 31, 2013 Non-recurring basis Significant Unobservable Inputs (Level 3) Cortaid
Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis
Impairment charges on intangible assets	$ 5.7	$ 5.4	$ 31.5	$ 551.6	$ 93.8
Fair value of assets measured on nonrecurring basis						$ 45.1	$ 37.8	$ 1.0